A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma

2003 ◽  
Vol 106 (3) ◽  
pp. 372-374 ◽  
Author(s):  
Hiroshi Hirata ◽  
Katsusuke Naito ◽  
Satoru Yoshihiro ◽  
Hideyasu Matsuyama ◽  
Yutaka Suehiro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Single Nucleotide Polymorphism ◽  
Matrix Metalloproteinase ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide ◽  
Conventional Renal Cell Carcinoma ◽  
Matrix Metalloproteinase 1 ◽  
The Matrix

scholarly journals Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib

Kidney Cancer ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 139-149
Author(s):  
Benoit Beuselinck ◽  
Thomas Van Brussel ◽  
Annelies Verbiest ◽  
Maxime Vanmechelen ◽  
Gabrielle Couchy ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Single Nucleotide Polymorphism ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Validation Cohort ◽  
Clear Cell ◽  
Nucleotide Polymorphism ◽  
Discovery Cohort ◽  
Cell Renal Cell Carcinoma ◽  
Single Nucleotide

BACKGROUND: Previously, we have shown a correlation between single nucleotide polymorphism (SNP) rs307826 in vascular endothelial growth factor receptor-3 (VEGFR3) and outcome in metastatic clear-cell renal cell carcinoma (m-ccRCC) patients treated with sunitinib. OBJECTIVE: We aimed to validate this finding in an independent patient series. METHODS: m-ccRCC patients receiving sunitinib as first-line targeted therapy were included in a validation cohort. Endpoints were response rate (RR), progression-free survival (PFS) and overall survival (OS). We also updated survival data of our discovery cohort as described previously. RESULTS: Eighty-four patients were included in the validation cohort. rs307826 AG/GG-carriers had a shorter PFS (8 versus 12 months, p = 0.04) and a trend towards a shorter OS (18 versus 27 months, p = 0.22) compared to AA-carriers. In the total series of 168 patients (from the discovery cohort, as described previously, and the validation cohort), rs307826 AG/GG-carriers had a poorer RR (29% versus 53%, p = 0.008), PFS (8 versus 15 months, p = 0.0002) and OS (22 versus 31 months, p = 0.004) compared to AA-carriers. rs307826 was independently associated with PFS and OS on multivariate analysis. CONCLUSION: VEGFR3 rs307826 seems to be associated with outcome on sunitinib in m-ccRCC. Its impact highlights the role of VEGFR3 in ccRCC pathogenesis and as a target of sunitinib.

Leukocyte telomere length and hTERT genetic polymorphism rs2735940 influence the renal cell carcinoma clinical outcome

2020 ◽  
Vol 16 (18) ◽  
pp. 1245-1255
Author(s):  
Mariana Morais ◽  
Francisca Dias ◽  
Telma Resende ◽  
Inês Nogueira ◽  
Jorge Oliveira ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Single Nucleotide Polymorphism ◽  
Cell Carcinoma ◽  
Telomere Length ◽  
Renal Cell ◽  
Leukocyte Telomere Length ◽  
Healthy Individuals ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide

Aim: Analysis of the genetic hTERT-1327 C>T (rs2735940) influence on leukocyte telomere length (LTL) and tumor development, progression and overall survival in renal cell carcinoma (RCC) patients. Materials & methods: Using leukocyte DNA of RCC patients and healthy individuals, LTL measurement and allelic discrimination of rs2735940 was performed by real-time PCR. Results: RCC patients showed shorter LTL than healthy individuals and LTL increased with clinical stage. CC+TC genotypes healthy carriers’ presented shorter LTL. However, no statistical association between the different genotypes and RCC risk. Nevertheless, CC homozygous presented a reduced time to disease progression and a lower overall survival. The use of hTERT-1327 single nucleotide polymorphism information increased the capacity to predict risk for RCC progression. Conclusion: In fact, in healthy individuals, hTERT-1327 CC+TC genotypes were associated with shorter LTL, and this single nucleotide polymorphism was associated with time to disease progression, being a promising potential prognosis biomarker to be used in the future.

Sign in / Sign up

Export Citation Format

Share Document